SBIR/STTR Research Award

Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ

Award identifier a3b4d56e576350b5371af2ff88197feae2ed764edaed379f7758e72933caa7ffAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$2,181,764

Program and phase

SBIR · Phase II

Award year

2017

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
BIOVINC, LLC
Proposal award date
2017-03-15
Contract end date
2020-02-29
UEI
NNEJMJ7KDAF1
Solicitation number
PA15-269
Topic code
101

Research abstract

ABSTRACT Sinceseveral nitrogen containing bisphosphonateNBPdrugs have been approved for the treatment of Pagetandapos s diseasemetastatic disease of the boneand osteoporosisThe later indication has led to the prescription of these drugs to millions of patients in the lastyearsPatients who have bone metastasis receive very large doses of these drugsin some cases receiving the amount in one month that osteoporosis patients receive in a yearThe NBPs are effective and safe drugs which have reduced morbidity and mortality for a large number of patients with osteoporosis and bone metastatic diseaseA side effect now notoriously associated with NBP use is BRONJbisphosphonate associated osteonecrosis of the jawWhile the overall risk of developing this side effect is smallit is associated with significant morbiditySome have advocated for drug holidays prior to dental worka risk factor for the development of BRONJhoweverthis is not an option for the patients with cancer and bone metastases who are at high risk for fractureIn our Phase I studywe developed a novel strategy for preventing or treating BRONJ based on the removal of anti resorptive NBPs by local application of a secondary fluorescent bisphosphonateFL BPthat does not have effects on bone metabolismIn our Phase II study we will build on the feasibility demonstrated in Phase I using three specific aims with the goal of generating data to demonstrate clinical utility and safety of this conceptAimSynthesize the novel indocyanine greenICGbased near infraredNIRFL BP conjugatesICG BPsbased on the antiresorptive inactive para pyridyl ethanebisphosphonatep PyrEBPAimTest the effectiveness of the ICG BP from Aimin a murine model to prevent ONJ via local deliveryand AimDevelop a method for compound analysis in plasma and other tissues and carryout initial PK and toxicology studiesThe product ultimately developed in this project will be delivered locally to the oral cavity without significant systemic effects and will have a near infrared fluorescent moiety that allows visualization of the loading of this new drug and therefore the displacement of the active NBPthus serving as an indicator for safely initiating a dental procedureIf successfulthis product would find great use to help remove the fear of this debilitating side effect of NBP use for these patient populations PROJECT NARRATIVE Osteonecrosis of the jawONJis a debilitating side effect of the use of drugssuch as nitrogen containing bisphosphonatesNBPsthat reduce bone loss for diseases such as osteoporosis and bone metastasis from cancerONJ is very rare but causes significant morbidity and no treatment is currently availableHere we outline a preventative strategy for this complication of bisphosphonate therapy which would be of significant value to the public health

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

11 SBIR/STTR records share this UEI (2015–2024). Reported award amounts total $10,069,192. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.